Gianpiero Di Leva

List of Publications by Year in Descending Order

35 papers	8,229 citations	28 h-index	38 g-index
38 ext. papers	8,859 ext. citations	13 avg, IF	5.74 L-index

#	Paper	IF	Citations
35	Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. *Cancers*, **2019**, 11,	6.6	73
34	Loss of miR-204 expression is a key event in melanoma. *Molecular Cancer*, **2018**, 17, 71	42.1	17
33	Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. *Nature Communications*, **2017**, 8, 14909	17.4	47
32	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. *Scientific Reports*, **2017**, 7, 3140	4.9	38
31	miRNAs in bone metastasis. *Expert Review of Endocrinology and Metabolism*, **2017**, 12, 451-461	4.1	3
30	miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. *Cancer Research*, **2016**, 76, 5562-72	10.1	67
29	A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E3355-64	11.5	60
28	Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	32
27	The Role of microRNAs in Cancer **2015**, 80-88		2
26	miRNA clusters as therapeutic targets for hormone-resistant breast cancer. *Expert Review of Endocrinology and Metabolism*, **2015**, 10, 607-617	4.1	16
25	MicroRNA profiles discriminate among colon cancer metastasis. *PLoS ONE*, **2014**, 9, e96670	3.7	88
24	Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. *Modern Pathology*, **2014**, 27, 851-62	9.8	34
23	Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	25
22	MicroRNAs in Solid Tumors **2014**, 97-127		0
21	MicroRNAs in cancer. *Annual Review of Pathology: Mechanisms of Disease*, **2014**, 9, 287-314	34	1157
20	MicroRNAs as anti-cancer therapy. *Current Pharmaceutical Design*, **2014**, 20, 5328-35	3.3	46
19	miRNA profiling of cancer. *Current Opinion in Genetics and Development*, **2013**, 23, 3-11	4.9	322

18	Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. *PLoS Genetics*, **2013**, 9, e1003311	6	117
17	MiR-34a/c-Dependent PDGFR-Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. *PLoS ONE*, **2013**, 8, e67581	3.7	82
16	The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. *Frontiers in Oncology*, **2013**, 3, 153	5.3	78
15	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. *Molecular Oncology*, **2012**, 6, 458-72	7.9	122
14	MicroRNA in cancer: new hopes for antineoplastic chemotherapy. *Upsala Journal of Medical Sciences*, **2012**, 117, 202-16	2.8	34
13	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16570-5	11.5	142
12	EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. *Nature Medicine*, **2011**, 18, 74-82	50.5	328
11	Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. *Diagnostic Molecular Pathology*, **2010**, 19, 135-43		54
10	MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. *Journal of the National Cancer Institute*, **2010**, 102, 706-21	9.7	269
9	Roles of small RNAs in tumor formation. *Trends in Molecular Medicine*, **2010**, 16, 257-67	11.5	211
8	Reprogramming of miRNA networks in cancer and leukemia. *Genome Research*, **2010**, 20, 589-99	9.7	287
7	Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. *Cancer Cell*, **2010**, 18, 367-81	24.3	356
6	miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. *Cancer Cell*, **2009**, 16, 498-509	24.3	672
5	MicroRNA signatures in human ovarian cancer. *Cancer Research*, **2007**, 67, 8699-707	10.1	1251
4	MicroRNAs: fundamental facts and involvement in human diseases. *Birth Defects Research Part C: Embryo Today Reviews*, **2006**, 78, 180-9		70
3	Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. *Cancer Research*, **2006**, 66, 10287-91	10.1	44
2	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *New England Journal of Medicine*, **2005**, 353, 1793-801	59.2	2041
1	TOP promoter elements control the relative ratio of intron-encoded snoRNA versus spliced mRNA biosynthesis. *Journal of Molecular Biology*, **2004**, 344, 383-94	6.5	12